Moleculin reports FY2025 results; MIRACLE trial shows 40% blinded CRc rate in first 30 R/R AML patients

Moleculin Biotech, Inc.

FY2025 R&D expense $15.9M (down from $17.7M), G&A $9.2M; cash $8.9M at year-end; $8.3M raised in Q1 2026; cash runway into Q3 2026.
MIRACLE trial (Phase 2B/3) Annamycin + cytarabine in R/R AML: blinded CRc 40% in first 30 subjects; interim unblinding for 45 patients expected mid-2026.
Pipeline progress: WP1066 Phase 1 pediatric brain tumor trial shows safety and immune response; Annamycin GBM collaboration and pancreatic cancer study initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.68

Moleculin Biotech, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-008949

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.